Risk Management and Healthcare Policy (Jul 2023)

A Prospective Case-Control Study Examining the Relationship Between Frailty and Serum Myostatin in Older Persons with Chronic Heart Failure

  • Wang Q,
  • Wang H,
  • Tian H,
  • Niu S,
  • Xu R

Journal volume & issue
Vol. Volume 16
pp. 1343 – 1349

Abstract

Read online

Qing Wang,1 Hongyan Wang,2 Haitao Tian,2 Shaoli Niu,2 Ruyi Xu1 1Department of the Sixth Health Care, The Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100048, People’s Republic of China; 2Department of Geriatrics, The Sixth Medical Center, Chinese PLA General Hospital, Beijing, 100048, People’s Republic of ChinaCorrespondence: Hongyan Wang, Department of Geriatrics, The Sixth Medical Center, Chinese PLA General Hospital, No. 6 Fucheng Road, Haidian District, Beijing, 100048, People’s Republic of China, Tel +86-10-66957726, Email [email protected]: Frailty affects the prognosis and management of patients with heart failure, and is often related with sarcopenia. Also, the serum myostatin (MSTN) involved in the development of sarcopenia and frailty. This study aimed to determine the connection between MSTN level and frailty in older adults with chronic heart failure (CHF).Methods: This prospective case-control study enrolled older adult patients with CHF between May 2019 and May 2021, and analyzed their clinical data.Results: In this study 75 older adults with CHF were included, 29 of whom were frail. The B-type natriuretic peptide (BNP) levels were significantly higher in frail older adults with CHF than in older adults with CHF who were not frail (316.82 ± 235.64 pg/mL vs 198.61 ± 112.58 pg/mL; P = 0.016). The MSTN levels were significantly higher in frail participants than in participants who were not frail (2.93 ± 1.35 ng/mL vs 2.24 ± 0.84 ng/mL; P = 0.018). Based on multivariable analysis the BNP (odds ratio [OR] = 1.004, 95% confidence interval [CI] = 1 0.001– 1.008; P = 0.018) and MSTN (OR = 1.772, 95% CI = 1.079– 2.912; P =0 0.024) levels were independently associated with frailty in older adults with CHF.Conclusion: MSTN is a promising biomarker of frailty in elderly patients with CHF.Keywords: myostatin, B-type natriuretic peptide, frailty, chronic heart failure

Keywords